Kazia Therapeutics

Kazia Therapeutics Limited is an oncology-focused biotechnology company. KZA is focused on the development of novel anti-cancer drugs based on two proprietary drug technologies known as Super-benzopyrans and Anti-tropomyosins. The company is headquartered in Sydney, Australia, with an office in New Haven, Connecticut in the US.

The company delisted from the ASX in November 2023.

Details

Level 24, Three International Towers , 300 Barangaroo Ave SYDNEY NSW 2000

02 9472 4100

secretary@novogen.com

www.kaziatherapeutics.com

Lists and Charts

Share price

Kazia Therapeutics

Closing price for the last 90 trading days

View ASX Chart

Revenue

Rank		Company	#
894^th	-	Kazia Therapeutics	$3.39m

1097 public companies - non WA ranked by total revenue

View Full List

Company Share Transactions

Company Activity

	NEW ROLE: J Friend,	03 Nov 2022
	NEW ROLE: K Krumeich,	03 Nov 2022
	NEWS: Tagged in Where markets meet medicine; a biotech entrepreneur at the tip of the spear	14 Feb 2022
	NEW ROLE: P Leong,	24 Nov 2020
	NEW ROLE: G Hirsch,	24 Nov 2020
	NEW ROLE: G Heaton, Dir:Finance & Administration	24 Nov 2020
	NEW ROLE: Kate Hill, Company Secretary	24 Nov 2020
	NEW ROLE: Steven RS Coffey, Non-Executive Director	03 Nov 2020

Related Information

Access to our data for Kazia Therapeutics is only available to paid subscribers with Data & Insights access.

Data & Insights is Western Australia's most accurate and comprehensive business listings and searchable database.

Kazia Therapeutics is included in 1 list - Public Companies - non WA.

For public companies, our subscribers have access to the list of executives and directors along with company financials, director's interests and remuneration.

Subscribe today